Histocell SL:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Histocell SL - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10928
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:17
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スペイン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥27,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥54,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥81,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Histocell SL (Histocell), a subsidiary of Noray Biosciences Group, is a biopharmaceutical company that develops cell therapy and tissue engineering products for regenerative medicine. The company provides Wharton Gel Complex, medical devices, contract manufacturing and cell therapy programs, among others. Its wharton gel complex is a cosmetic ingredient with skin protective and regenerative properties. Histocell develops, manufactures and sells medical devices and drugs such as Cicatrigel, Histogel and Histobone, among others. The company also provides biocompatibility tests, advanced molecular and cellular biology analytical services and biological research services. Histocell is headquartered in Derio, Spain.

Histocell SL – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Histocell SL, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Histocell SL, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Histocell SL, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Histocell SL, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Histocell SL, Medical Devices Deals, 2012 to YTD 2018 9
Histocell SL, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Histocell SL, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Histocell Enters Into Co-Development Agreement With Ferrer 11
Licensing Agreements 12
Luqa Pharma Enters into Licensing Agreement with Histocell for Reoxcare 12
Histocell Enters Into Licensing Agreement With IDIBELL For Acute Pulmonary Diseases Patent 13
Histocell SL – Key Competitors 14
Histocell SL – Key Employees 15
Histocell SL – Locations And Subsidiaries 16
Head Office 16
Other Locations & Subsidiaries 16
Joint Venture 16
Appendix 17
Methodology 17
About GlobalData 17
Contact Us 17
Disclaimer 17

List of Tables
Histocell SL, Pharmaceuticals & Healthcare, Key Facts 2
Histocell SL, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Histocell SL, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Histocell SL, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Histocell SL, Deals By Therapy Area, 2012 to YTD 2018 8
Histocell SL, Medical Devices Deals, 2012 to YTD 2018 9
Histocell SL, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Histocell Enters Into Co-Development Agreement With Ferrer 11
Luqa Pharma Enters into Licensing Agreement with Histocell for Reoxcare 12
Histocell Enters Into Licensing Agreement With IDIBELL For Acute Pulmonary Diseases Patent 13
Histocell SL, Key Competitors 14
Histocell SL, Key Employees 15
Histocell SL, Joint Venture 16

List of Figures
Histocell SL, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Histocell SL, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Histocell SL, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Histocell SL, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Histocell SL, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Histocell SL, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Histocell SL, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Histocell SL, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Histocell SL, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Histocell SL:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Erasmus MC:企業のM&A・提携動向(医療機器分野)
    Summary Erasmus MC (Erasmus) is a medical institute that provides educational programs such as graduate and doctoral programs in health sciences, biomedical sciences, molecular medicine and cardiovascular sciences through its graduate school, besides others. Erasmus offers patient care, education an …
  • Angelo, Gordon and Co.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Angelo, Gordon and Co. Mergers …
  • Schnitzer Steel Industries, Inc.:企業の戦略・SWOT・財務分析
    Schnitzer Steel Industries, Inc. - Strategy, SWOT and Corporate Finance Report Summary Schnitzer Steel Industries, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • EVRY ASA:企業の戦略・SWOT・財務分析
    SummaryEVRY ASA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Findings - Det …
  • Stemina Biomarker Discovery, Inc.(製薬・医療分野):企業M&A動向
    Summary Stemina Biomarker Discovery, Inc. (SBDI) is a metabolomics company. It discovers, develops and commercializes molecular biomarkers for the improvement of human health and drug safety. The company’s cell based assays arised from human embryonic stem (hES) cells and metabolomics. SBDI’s techno …
  • WGL Holdings, Inc.:企業の戦略・SWOT・財務分析
    WGL Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary WGL Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Camber Energy Inc (CEI):企業の財務・戦略的SWOT分析
    Camber Energy Inc (CEI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Sompo Japan Nipponkoa Holdings, Inc.:企業の戦略・SWOT・財務情報
    Sompo Japan Nipponkoa Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary Sompo Japan Nipponkoa Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Genesis Research and Development Corporation Limited (GEN)(製薬・医療分野):企業M&A動向
    Summary Genesis Research and Development Corporation Limited (Genesis) is a biotechnology company. The company develops therapeutics for the treatment of cancer and diseases of the immune system and and agricultural biotech projects. It offers technologies to deliver separate complementary strands o …
  • UMW Holdings Bhd (UMW):石油・ガス:M&Aディール及び事業提携情報
    Summary UMW Holdings Bhd (UMW) is a diversified company. The company operates through its business divisions such as automotive, equipment, manufacturing and engineering, and oil and gas. Its automotive business manufactures, assembles, markets and distributes passenger cars and commercial vehicles. …
  • Metso Corp (METSO):石油・ガス:M&Aディール及び事業提携情報
    Summary Metso Corp (Metso) is an industrial machinery company that provides sustainable technology and services. It offers products such as mining and construction aggregates processing equipments, conveyers, separators, air classifiers, slurry pumps, industrial valves and controls, and waste shredd …
  • HHV Solar Technologies Limited:企業のM&A・提携動向(発電分野)
    Summary HHV Solar Technologies Limited (HHV Solar), a subsidiary of Swelect Energy Systems Limited is a solar equipment manufacturer that provides silicon photovoltaic modules and solar technology based solutions. The company's products include mono crystalline solar photovoltaic modules, multi crys …
  • Cytori Therapeutics Inc (CYTX):医療機器:M&Aディール及び事業提携情報
    Summary Cytori Therapeutics Inc (Cytori) is a clinical stage cell therapy company. It develops cell therapies from autologous adipose-derived regenerative cells (ADRCs) for the treatment of cardiovascular disease, orthopedic conditions and gastrointestinal disorders. The company has two therapeutic …
  • Altin Yunus Cesme Turistik Tesisler A.S.:企業の戦略・SWOT・財務分析
    Altin Yunus Cesme Turistik Tesisler A.S. - Strategy, SWOT and Corporate Finance Report Summary Altin Yunus Cesme Turistik Tesisler A.S. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Extreme Reach, Inc.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Extreme Reach, Inc. Mergers and …
  • Allergan Plc (AGN):企業のM&A・提携動向(医療機器分野)
    Summary Allergan Plc (Allergan), formerly Actavis is a specialty pharmaceutical company, which focuses on the development, manufacturing, marketing and distribution of specialty branded, generic, bio-similar, branded generics and over-the-counter (OTC) products. It offers products in the areas of ce …
  • Eurazeo SA (RF):企業財務及び戦略的SWOT分析
    Summary Eurazeo SA (Eurazeo) is a financial consulting company that provides investment services. The company invests in financial services, consumer manufacturing, business services, media, technology, and telecommunication sectors. It provides detection and acquisition; retention and divestment an …
  • SMU S.A. (SMU):企業の財務・戦略的SWOT分析
    SMU S.A. (SMU) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • TELUS Corporation:企業のM&A・提携・投資分析
    TELUS Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's TELUS Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), div …
  • Nippon Chemiphar Co Ltd (4539):企業財務及び戦略的SWOT分析
    Summary Nippon Chemiphar Co Ltd (Nippon Chemiphar) is a pharmaceutical company that manufactures, sells, imports and exports ethical pharmaceuticals and diagnostic drugs. The company manufactures both new and generic drugs through divisions such as pharmaceutical business, diagnostics business and h …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆